Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
44.26
-0.45 (-1.01%)
At close: Dec 5, 2025, 4:00 PM EST
44.28
+0.02 (0.05%)
After-hours: Dec 5, 2025, 5:59 PM EST
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Dianthus Therapeutics stock have an average target of 68, with a low estimate of 46 and a high estimate of 100. The average target predicts an increase of 53.64% from the current stock price of 44.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 6 | 6 | 6 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 10 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $47 | Strong Buy | Maintains | $40 → $47 | +6.19% | Nov 10, 2025 |
| Wedbush | Wedbush | Buy Maintains $44 → $46 | Buy | Maintains | $44 → $46 | +3.93% | Nov 6, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $56 | Strong Buy | Initiates | $56 | +26.53% | Oct 14, 2025 |
| Clear Street | Clear Street | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +125.94% | Sep 17, 2025 |
| Stifel | Stifel | Strong Buy Maintains $52 → $65 | Strong Buy | Maintains | $52 → $65 | +46.86% | Sep 12, 2025 |
Financial Forecast
Revenue This Year
2.18M
from 6.24M
Decreased by -65.12%
Revenue Next Year
1.48M
from 2.18M
Decreased by -31.95%
EPS This Year
-3.72
from -2.55
EPS Next Year
-3.69
from -3.72
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.3M | 4.2M | ||||
| Avg | 2.2M | 1.5M | ||||
| Low | 1.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -47.1% | 93.1% | ||||
| Avg | -65.1% | -32.0% | ||||
| Low | -72.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.34 | -3.16 | ||||
| Avg | -3.72 | -3.69 | ||||
| Low | -4.39 | -4.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.